UK’s leading private cancer specialists
GenesisCare is a global organisation with over 400 cancer centres across the UK, US, Australia and Spain. In the UK we specialise in advanced and innovative cancer treatments and collaborate with oncologists and health professionals who share our vision of enabling fast access to world-class cancer care. The strength of our relationships with oncologists is key to our success, enabling us to build a strong governance framework and to be the first to introduce many new cancer treatments safely and effectively. Our strategy is to invest early in new evidence-based treatments and modalities that hold potential for improved life outcomes.
At our 14 oncology outpatient centres we provide these specialist services
Part of a global network of MRI-guided radiotherapy centres
We are the first to introduce MRIdian MRI-guided radiotherapy and have treated more than 100 patients including complex and difficult-to-treat tumours such as central lung, liver and pancreas.
Now in London
In the UK, GenesisCare has 14 outpatient oncology centres, including Bristol, Oxford, Cambridge and Windsor and a new £20million state-of-the-art centre in a partnership with Bupa Cromwell Hospital. It houses a Gamma Knife Icon, Varian Edge and in Spring 2021 the UK’s second MRIdian MR linac – making it the most advanced radiation oncology centre in Europe. The centre will specialise in neuro-oncology, complex and difficult-to-treat tumours in the abdomen and lung, as well as offering the latest techniques for breast and prostate.
World-class oncology centres
We are a patient-first organisation and aim to provide exceptional care in everything we do. Our centres carry the Macmillan Quality Environment Mark and many are rated good by the CQC. We embed wellbeing into our care pathways and provide a comprehensive emotional and physical support package of life-changing therapies such as exercise medicine and counselling through the charity, Penny Brohn UK – at no cost to our patients or their insurers.
Our services are closely governed through our clinical advisory teams, our pathways are designed around evidence-based protocols and we are rolling out specialist eMDT platforms to facilitate peer review, collaborative decision-making and clinician support.